1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Oct 2022
Admin
News Article

Zhiyi Biotech Received Clinical Approval From Us Fda For Sk10 In Chemotherapy Induced Diarrhea

Zhiyi Biotech Announced That Fda Has Approved The Company'S Investigational New Drug (Ind) Application To Develop Sk10 (Inactivated Bacteroides Fragilis) For The Treatment Of Chemotherapy-Induced Diarrhea (Cid) . The Approval Of This Ind Authorizes Zhiyi Biotech To Conduct Its Phase 1 Clinical Trial In The U.S. It'S Noteworthy That It Is The World'S First Ind Application Of Live Biotherapeutic Products (Lbps) With Cid As An Indication. Sk10, The First Bacteroides Fragilis-Based Lbp That Obtained Fda Ind Approval, Is Also The First Lbp Of Next-Generation Probiotics In China That Approved For Clinical Trial By Fda. Moreover, Zhiyi Biotech Becomes The First Company In China To Advance Inactivated Preparation Of Lbp To The Clinical Stage. This Achievement Is An Essential Milestone For Zhiyi, Signifying That Zhiyi Has Fully Penetrated The Technical And Registration Pathway Of Pre-Clinical Development Of Lbp To Both Fda And Nmpa.Sk10, An Inactivated Bacteroides Fragilis-Based Lbp, Has Shown Significant Efficacy On Cid Models. Pre-Clinical Studies Have Indicated That Sk10 Can Reduce The Toxicity Of Chemotherapeutic Drugs Towards Intestinal Epithelial Cells, Regulate The Expression Of Apoptosis-Related Proteins, Reduce Inflammatory Cytokines, And Enhance Mucosal Barrier Function, Thereby Effectively Inhibit The Inflammatory Response Of Intestinal Epithelial Cells Induced By Chemotherapy And Associated Diarrhea Symptoms. Meanwhile, This Preparation Has Better Safety For Cancer Patients And Is More Convenient For Commercialization.About Chemotherapy-Induced Diarrhea (Cid):Cytotoxic Drugs Or Targeted Therapy Can Cause Drug-Associated Diarrhea. Data Shows That The Overall Incidence Of Diarrhea Caused By 5-Fluorouracil And Irinotecan Is Of 50-80%, Whilst It Caused By Egfr Inhibitors Such As Afatinib, Neratinib And Pyrotinib Is Of 75-90%. However, Available Drugs For Cid Are Limited. For Example, Loperamide, As A Short-Term Symptomatic Treatment, And Octreotide, An Intravenous/Subcutaneous Injection, Serious Adverse Effects Have Been Reported For Both Drugs. Hence The Need For Effective Drugs Is Urgent.About Us:Guangzhou Zhiyi Biotechnology Co., Ltd. , As Clinical-Stage Biotech Leading In Lbps In China , Is Committed To The Research And Development Of Lbps, Based On The Next Generation Probiotics (Ngps). It Has Built Up A Complete Technical And Industrial Platform, Covering From The Isolation And Identification Of New Functional Strains To The Development Of Innovative Products

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!